SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DaiS who wrote (9650)6/15/1998 3:55:00 PM
From: VLAD  Read Replies (2) of 23519
 
DaiS,

I believe that a good chunk of the new scripts are actually regular MUSE patients whose refills ran out.

Edderd claims that Vivus has now offered to reimburse urologists who decide to titrate Viagra failures.

MUSE script numbers should slowly blip up as men who failed on Viagra slowly trickle into the urologists office. As I understand, Vivus is having the urologist give the Viagra patient a survey form to fill out. The patient will know about MUSE so that if the Viagra fails or has undesirable side effects, these men will know that there is an available alternative. I think this is a good plan.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News